January 31, 2020
Chugai Pharmaceutical racked up record sales and profits in the year ended December 2019, buoyed by the robust uptakes of the hemophilia treatment Hemlibra (emicizumab) and the I/O med Tecentriq (atezolizumab), the company said on January 30. In the year,...read more